Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MapLight Therapeutics, Inc. - Common Stock
(NQ:
MPLT
)
9.760
-0.430 (-4.22%)
Delayed Quote
Updated: 3:06 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
228,287
Open
10.16
Bid (Size)
9.720 (200)
Ask (Size)
9.800 (300)
Prev. Close
10.19
Today's Range
9.610 - 10.16
52wk Range
9.100 - 40.43
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MapLight Therapeutics to Participate in Upcoming Investor Conference
September 09, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
-41.8%
-41.8%
1 Month
-24.7%
-24.7%
3 Month
-72.9%
-72.9%
6 Month
-53.1%
-53.1%
1 Year
-46.8%
-46.8%
More News
Read More
MapLight Therapeutics Announces $150 Million Private Placement Financing
August 13, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-07-29: top gainers and losers in today's session.
↗
July 29, 2026
Via
Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session.
↗
July 29, 2026
Via
Chartmill
Which stocks are moving on Monday?
↗
July 27, 2026
Via
Chartmill
Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint
↗
July 27, 2026
Via
MarketBeat
Monday's session: top gainers and losers
↗
July 27, 2026
Via
Chartmill
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
July 27, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
July 27, 2026
Via
Chartmill
These stocks that are showing activity before the opening bell on Monday.
↗
July 27, 2026
Via
Chartmill
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
July 27, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics Announces Changes to Board of Directors
June 24, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
June 22, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
↗
June 08, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
↗
May 31, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
↗
May 30, 2026
Via
The Motley Fool
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
↗
May 30, 2026
Via
The Motley Fool
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold?
↗
May 15, 2026
Via
The Motley Fool
Topics
Derivatives
Regulatory Compliance
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics to Participate in Upcoming Investor Conferences
May 08, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April
↗
May 04, 2026
Via
The Motley Fool
Topics
Derivatives
Regulatory Compliance
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 01, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data
↗
April 22, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 26, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is MapLight Therapeutics, Inc. - Common Stock publicly traded?
Yes, MapLight Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does MapLight Therapeutics, Inc. - Common Stock trade on?
MapLight Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MapLight Therapeutics, Inc. - Common Stock?
The ticker symbol for MapLight Therapeutics, Inc. - Common Stock is MPLT on the Nasdaq Stock Market
What is the current price of MapLight Therapeutics, Inc. - Common Stock?
The current price of MapLight Therapeutics, Inc. - Common Stock is 9.760
When was MapLight Therapeutics, Inc. - Common Stock last traded?
The last trade of MapLight Therapeutics, Inc. - Common Stock was at 10/01/26 03:06 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
